Chemotherapy Treatment in Gastric Cancer
Publication
Article
Special ReportsGastrointestinal Cancers (Issue 4)
Volume 4
Issue 1
Eric Van Cutsem, MD, PhD, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Eric Van Cutsem, MD, PhD, at University Hospitals Gasthuisberg/Leuven in Leuven, Belgium, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Clinical Pearls:
- Using trastuzumab or other anti-HER2 agents when treating patients with gastric cancer does not eliminate the need to use chemotherapy.
- Patients with gastric cancer are often in poor health to begin with and have low tolerance levels and fast occurrances of resistance after undergoing chemotherapy.
- There is room for growth and improvement in chemotherapy in order to determine if the treatments can contain less toxicities, which remains a challenge for patients in regards to their overall means of survival.
Articles in this issue
Expert Investigators Discuss Emerging Therapies for GI Cancers
Predictors of Toxicity in Colon Cancer Treatment Identified
Many Biliary Tract Cancers Harbor Actionable Mutations
KRAS Mutant ctDNA Assay Performance Comparable in Urine and Plasma for Advanced CRC
Safety of Regorafenib Confirmed in Patients With mCRC and High PFS
Chemotherapy Treatment in Gastric Cancer
Pembrolizumab in Advanced Gastric Cancer Treatment
Onartuzumab for Gastroesophageal Adenocarcinoma
FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer
Recent Videos
Related Content
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025Article
In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More
